Figure 1. Objective Response Rate, Progression-Free Survival, and Overall Survival in Patients With a High vs Low Harmonized Tumor Mutation Burden (TMB).

Data are from the pooled cohort of 1552 patients with non–small cell lung cancer treated with programmed death ligand–1 blockade from the Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Stand Up To Cancer/Mark Foundation data sets. HR indicates hazard ratio; NR, not reached.